You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back


The FIRST Respiratory syncytial virus (RSV)  Vaccine with an adjuvant NOW AVAILABLE in the Philippines, with demonstrated efficacy for patients aged 60 years and older1-6

Nucala battle tested campaign imagery

Make a difference for your symptomatic COPD patients at risk of exacerbations7

 Therapy Areas


Vaccinate now for protection that last8*

 More Information


  1. Arexvy Certificate of Product Registration;
  2. Arexvy Local Prescribing Information GDS02 IP101 24 May 2023
  3. Falsey AR, Walsh EE, House S, et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults— a global study during the 2017-2019 epidemic seasons (hospitalized acute respiratory tract infection [HART I] study). Open Forum Infect Dis. doi:10.1093/ofid/ofab491
  4. Wilson E et al. Safety and efficacy of mRNA-1345, an mRNA-based vaccine against respiratory syncytial virus, in adults 60 years and older (oral presentation). Presented at RSSVW'23, 22-24 February 2023, Lisbon, Portugal.
  5. Papi A et al. N Engl J Med 2023;388(7):595–608
  6. Respiratory syncytial virus vaccine, Global Full Prescribing Information;; retrieved on February 2024
  7. Trelegy Prescribing Information version number : GDS06/IPI06.1 Revision date: 08 June 2021
  8. Shingrix Prescribing Information GDS07/IPI02 / Date of issue: 14 June 2022

Trade marks are owned by or licensed to GSK group of companies.

Kindly forward all adverse events and product complaint to GSK Philippines via these contact details: Adverse event:; Product complaint: or 0917 889 7050

PM-PH-NA-WCNT-190003 | April 2024